Open track

In programme

76 sessions 236 presentations View the programme

About

This track is co-produced by the European Union Drugs Agency (EUDA).

It welcomes submissions on topics related to addictive behaviours that may not fall within the specific focus of the other co-produced tracks.

Sessions

Wednesday, 23 October

08:30

Official opening

08:30 to 09:00

Auditorium I

Plenary session

09:00

Meeting the needs of service users and service providers

Plenary session 1

09:00 to 10:30

Auditorium I

Plenary session

10:50

Advances in drug treatment

10:50 to 12:20

Auditorium II

Oral presentation session

Innovative health approaches

10:50 to 12:20

Auditorium III

Oral presentation session

Sex, gender and diversity in drugs

10:50 to 12:20

Auditorium IV

Oral presentation session

Advancing addiction research: global perspectives and collaborative initiatives

10:50 to 12:20

Auditorium VI

Oral presentation session

Prevalence of opioids and related harms

10:50 to 12:20

Auditorium VIII

Oral presentation session

Support for recovery

10:50 to 12:20

Room 1.07

Short communication session

Alcohol: policy and harm reduction

10:50 to 12:20

Room 1.08

Short communication session

Closed session

ECR Programme — Scientific writing

10:50 to 12:20

Room 1.10

Workshop

Evaluation of drug consumption rooms: guidance step by step

10:50 to 12:20

Room 1.15

Workshop

13:20

Legal shifts and their Impact on drug use and sentencing

13:20 to 14:50

Auditorium IV

Oral presentation session

Gender and substance use

13:20 to 14:50

Auditorium VIII

Oral presentation session

Meetings the needs of women who use drugs or alcohol

13:20 to 14:50

Room 1.06

Short communication session

Methods and measurement

13:20 to 14:50

Room 1.08

Short communication session

15:00

The recovery journey

15:00 to 16:30

Auditorium III

Oral presentation session

The growing threat of synthetic drugs – developments and responses in North America and Europe

15:00 to 16:30

Auditorium VIII

Oral presentation session

Inequalities and needs of migrant groups

15:00 to 16:30

Room 5C

Oral presentation session

Problematic gambling and gaming

15:00 to 16:30

Room 1.07

Short communication session

Conceptualising health and harms

15:00 to 16:30

Room 1.08

Short communication session

16:50

Strengthening quality in substance use disorders treatment

16:50 to 18:20

Auditorium II

Oral presentation session

NPS: trends, concerns and response strategies

16:50 to 18:20

Auditorium III

Oral presentation session

Psychedelics 1

16:50 to 18:20

Auditorium VIII

Oral presentation session

Opioid treatment 1

16:50 to 18:20

Room 5B

Oral presentation session

Motivations for use

16:50 to 18:20

Room 5C

Oral presentation session

Opioids: trends, use and treatments

16:50 to 18:20

Room 1.06

Short communication session

Capacity-building through competencies for the substance use workforce

16:50 to 18:20

Room 1.10

Workshop

18:30

Why are we not doing better at reducing drug-related deaths?

18:30 to 19:30

Auditorium I

Big debate

Thursday, 24 October

09:00

Synthetic opioids and psychedelics: new opportunities & new challenges for clinical practice

Plenary session 2

09:00 to 10:30

Auditorium I

Plenary session

Expert knowledge elicitation to complement and enhance data collection and monitoring efforts.

09:00 to 10:30

Room 1.10

Workshop

Workshop on conducting drug research in prison: Challenges and key recommendations from the European experience

09:00 to 10:30

Room 1.15

Workshop

10:50

Opioid treatment 2

10:50 to 12:20

Auditorium III

Oral presentation session

Evidence informed drug and alcohol policy

10:50 to 12:20

Auditorium VI

Oral presentation session

Emerging drug harms, DCRs and other responses

10:50 to 12:20

Auditorium VII

Short communication session

Innovative methods for understanding drug markets and policy

10:50 to 12:20

Room 5A

Oral presentation session

Challenges, threats, and opportunities in addiction publishing today

10:50 to 12:20

Room 1.05

Oral presentation session

Natural language processing for addiction research: a practical primer

10:50 to 12:20

Room 1.06

Workshop

EU research funding opportunities

10:50 to 12:20

Room 1.07

Workshop

Contemporary issues

10:50 to 12:20

Room 1.08

Oral presentation session

Closed session

ECR Programme — An introduction to theory in qualitative research

10:50 to 12:20

Room 1.10

Workshop

13:20

Novel neurobiology - cannabis, cognition and craving

13:20 to 14:50

Auditorium III

Oral presentation session

Nitazene-related fatal and non-fatal toxicity in Europe: hospital emergency perspective

13:20 to 14:50

Auditorium VIII

Oral presentation session

Public health and safety impacts of cannabis legalization in Canada: five years in review

13:20 to 14:50

Room 5A

Oral presentation session

Pregnancy, drug use and care

13:20 to 14:50

Room 5B

Oral presentation session

Women's realities of drug use

13:20 to 14:50

Room 1.08

Oral presentation session

Scenarios for the future of addictions fields by 2040

13:20 to 14:50

Room 1.10

Workshop

Writing for 'addiction' journals for early career researchers with DEPP Editors-in-Chief

13:20 to 14:50

Room 1.15

Workshop

15:00

NPS: Pharmacological Characterization and Substance Analysis

15:00 to 16:30

Auditorium III

Oral presentation session

A unique care model for inpatient addictions and tri-morbidity within an acute UK hospital

15:00 to 16:30

Room 5C

Oral presentation session

Novel psychoactive substances and latest drug trends in Asia and Pacific countries

15:00 to 16:30

Room 1.05

Oral presentation session

From genes to brains

15:00 to 16:30

Room 1.06

Short communication session

Drug trends: experiences from Brazil, the Netherlands, Portugal, and Spain

15:00 to 16:30

Room 1.08

Oral presentation session

How to respond to real-time drug alerts in European countries ?

15:00 to 16:30

Room 1.15

Workshop

16:50

How can the voices of people with lived experience, clients and communities impacted by drug use better inform clinical practice, research and the policy agenda?

16:50 to 17:50

Auditorium I

Big debate

Mixed methods for understanding drug use

16:50 to 18:20

Auditorium III

Oral presentation session

Misuse of medicines

16:50 to 18:20

Auditorium VIII

Oral presentation session

Hospital-based treatments

16:50 to 18:20

Room 5B

Oral presentation session

From old to new: changes in drug use

16:50 to 18:20

Room 5C

Oral presentation session

ScaleUp: Options for scalable psychosocial and pharmacological treatment of stimulant use disorder

16:50 to 18:20

Room 1.08

Oral presentation session

Toolkit to Deal with Female Drug User Victims of Gender-Based Violence

16:50 to 18:20

Room 1.15

Workshop

17:50

EUDA presentation

17:50 to 18:20

Auditorium I

Major session

Friday, 25 October

09:00

Joining the dots: the relationship between substance use and other health conditions

Plenary session 3

09:00 to 10:30

Auditorium I

Plenary session

10:50

The ripple effect: International developments in the opioid market and their potential implications for European public health and security

10:50 to 12:20

Auditorium I

Major session

Psychedelics 2

10:50 to 12:20

Auditorium VI

Oral presentation session

Unravelling the nexus: understanding drug-related violence across Europe

10:50 to 12:20

Auditorium VIII

Oral presentation session

Online monitoring

10:50 to 12:20

Room 5B

Oral presentation session

Substance use and treatment needs across European prisons

10:50 to 12:20

Room 5C

Oral presentation session

How can cannabis policy goals inform the development of evaluation indicators?

ECR Programme — EU research funding opportunities

10:50 to 12:20

Room 1.10

Workshop

Intimate partner violence perpetration: The ADVANCE-Digital Programme for men

10:50 to 12:20

Room 1.15

Workshop

13:20

Young people and drugs

13:20 to 14:50

Auditorium III

Oral presentation session

Addressing diverse treatment needs

13:20 to 14:50

Auditorium VI

Oral presentation session

Regulating cannabis supply policies in Europe: navigating the long road to change

13:20 to 14:50

Auditorium VIII

Oral presentation session

Future of opioid markets in Europe: Foresight approaches

13:20 to 14:50

Room 1.10

Workshop

15:00

Future paradigms for drug markets and drug policies?

Closing session

15:00 to 16:40

Auditorium I

Plenary session

16:40

Closing ceremony

16:40 to 16:50

Auditorium I

Plenary session

Presentations

Wednesday, 23 October

09:00

Keynote presentation

Involving people with lived experience in the development and delivery of substance use interventions: opportunities to enhance quality and outcomes

How do we do more to safeguard the mental health and well-being of healthcare professionals in the substance misuse area

10:50

Lisdexamfetamine in the treatment of methamphetamine dependence, a randomised controlled trial

NIDA International Program Research Update

Understanding the research capacity of Australian alcohol and other drug services

Managing Benzodiazepine Dependence and High-Risk Use with Opiates: A feasibility study of a Co-produced Intervention

Treatment of benzodiazepine withdrawal through taper dosing is most successful when it lasts less than 6 months.

Report from LX24 side event - Strengthening networks and sharing innovation in practices on research and surveillance in the drugs field

10:50 to 12:20

Auditorium VI

Vickna Kasinather, Charles Parry

Oral presentation

The effectiveness of naloxone in reversing opioid overdose: The European naloxone outcome research study (NalPORS)

Substance Use, Sexual Pleasure and Recovery among gbMSM: Addressing Sexual Satisfaction in Addiction Interventions

Modelling the wider socio-economic costs of problematic opioid use in the UK

Twenty-one years of heroin-related mortality in Australia: Joinpoint regression analysis of trends by age and gender

Underestimate of deaths due to specific opioids in England and Wales for a decade

Prevalence of opioid dependence in Scotland, 2015-2020: results from a Multi Parameter Estimation of Prevalence model

Addressing gender, diversity, and precarity: participatory research to transform addiction services in Canada

A global perspective on the emotions associated with chemsex practice to better support the community

User experiences of a digital intervention among individuals on opioid use disorder treatment in Kenya

Chemsex Professional Training Program in Catalonia

Cultural safety and telecare. A systematic scoping review and sector survey

The role of physical activity in preventing relapse: the perception of participants

Exploring Personal Strengths and Resources in Long-Term Substance Use Disorder Recovery: Insights from Lived Experience

The effect of Individual Placement and Support on employment outcomes for individuals with substance use disorders

Understanding the process of drug addiction recovery through learning from lived experience

Emotional dysregulation as a predictor of cocaine severity and withdrawal symptoms

A systematic review of the nuances of attachment, bonding and parenting for mothers in addiction recovery

The role of specialist substance use and addiction treatment in building recovery capital

Recovery does not stop at discharge: A qualitative evaluation of Alcohol Recovery Navigators in North East England.

The gendered impacts of drug stigma - a qualitative study with 10 street-involved women who use drugs in Porto

“I drink less and that's no small matter”: A qualitative study of a managed alcohol program evaluation in Barcelona.

Barriers for treatment in alcohol use disorders (AUD) – the role of stigmatization: A consumer’s perspective

Corporate political activities of the Portuguese Alcohol Industry post-COVID-19, where do we stand?

10:50 to 12:20

Room 1.08

Francisca Pulido Valente

Short communication

A Longitudinal Evaluation of an Alcohol Related Brain Injury Specialist Residential Rehabilitation Service

Pragmatic case finding as a strategy to improve addressing alcohol in general practice – a mixed methods pilot study

An Alcohol Strategy for the Northwest Territories

The problematisation of alcohol in the Northern Territory: what did Alcohol Mandatory Treatment seek to address?

Embodied Storytelling: An Accessible Approach to Re-storying in the Recovery Process

Drug Consumption Rooms in Europe. Operational characteristics, capacities, services and its associated factors.

Managed Alcohol Programmes: a realist review to identify what works, for whom, and in what circumstance

13:20

Why is a gender perspective needed in the drug field? Insight from the latest European drugs data.

Navigating the Shift: Understanding the Dynamics of Cannabis Use in Germany Amidst Legalization Prospects

The perspective of transgender and non-binary people on their substance use trajectories and resilience processes

Smoking and nicotine use behaviours among women of reproductive age: a ten-year population study in England

Gender Compression Over Time in Measures of Cannabis Use by Age and Cohort in the United States

Phosphatidylethanol as a screening tool for alcohol consumption during pregnancy

Digital Invisibility: Presence of Substance Use Disorder Treatment Programs for Women in the Caribbean

Utilization of pharmacological treatment for alcohol use disorder in pregnancy in the total Swedish population

The effects of legislative measures for 3-MMC in the Netherlands on drug sample composition and self-reported effects.

The important role of social connectedness in the alcohol use of women aged 50 to 62 years.

Leximetric analysis of drug laws and evaluation of outcomes: cross-country analyses approach

Barriers and Enablers in Disclosing Substance Use by Pregnant Women in Australian prisons

Judge Demographics and Their Impact on Sentencing of Drug Crimes

In favor or against the codependency concept: A narrative review of arguments in scientific literature

13:20 to 14:50

Room 1.08

Alexis Beaulieu-Thibodeau

Short communication

The relationship between cannabis and tobacco use - a systematic review and meta-analysis

Prevalence and trends of ethanol and drugs among arrested drivers in Norway in the period 2013-2023

Tuning In for Chemistry: Setting up a multi-instrument mobile drug-checking lab at a 7-day psychedelic music festival

Alcohol prevention: a review using Topic Modelling

Cannabis and mental health in Germany: a baseline estimation pre legalization

Evaluation of heroin-assisted treatment in Norway: Protocol for a mixed methods study

13:20 to 14:50

Room 1.08

Lars Henrik Myklebust

15:00

Oral presentation

Canada synthetic opioids situation

Emerging drug trends – what are the issues and how can we strengthen preparedness

US experience with synthetic drugs

The U.S. international perspective including the Global Coalition

A Safer Downtown for All: Including People Who Use Drugs in the Solutions to Social Disorder

Superiority and cost-effectiveness of Individual Placement and Support for people with alcohol and drug dependence

Building Capacity For Future Evaluation of Residential Treatment for People Experiencing Homelessness and Addiction

Migrants in the criminal justice system: A qualitative understanding of the role of substance use in their lives

Drug use and (non-)use of addiction treatment by women in French Guyana: gender and migration effects

Challenges and support needs among persons with a migration background who use drugs in four metropolitan cities

15:00 to 16:30

Room 5C

Wouter Vanderplasschen

Oral presentation

"Boxing Clever Cork saved my life": an evaluation of an Irish early addiction recovery initiative

Envisioning youth-dedicated overdose prevention and drug consumption sites in Canada and Portugal

Exploring the biopsychosocial needs of ageing heroin users in treatment in Malta: implications for service provision

What increases the risk of problem gambling in adolescents? Findings from the Greek arm of the ESPAD study

Financial hardship and gambling severity: a population-based study in Finland

Mental health in people with hazardous cannabis and alcohol use - insights from a study of regulated cannabis sales

Harmful types of gambling: Changes and emerging trends in longitudinal helpline data

Late relapse among ex-smokers using e-cigarettes following a quit attempt: a prospective one-year follow-up study

Accessibility, local socioeconomic disadvantage and expenditure on electronic gambling machines

Substance induced psychosis among persons with concurrent mental health and substance use disorders under pandemic

Extended hours of video game play and negative physical symptoms and pain

Religiosity and gambling - moderating role of reflective thinking: A Polish-Georgian Study

Associations between mental health and substance use in higher education students in Germany – a cross-sectional study

Suicide by people in contact with drug and alcohol services: a national study 2021 to 2022

Psychoactive Substance Use Among Russian Migrants Relocated to Georgia Following the 2022 Ukrainian Invasion

Online Gambling Companies’ Interpretation of Duty of Care and its Implication for Responsibilisation of Gambling Related Harm

Refugees & drug use in Belgium: A national study on drug-related intervention needs in the reception setting (DrugInt)

Barriers and facilitators for accessing HCV care in PWID: a qualitative study using an intersectional approach

16:50

Application of the International Standards for the Treatment of Drug Use Disorders and the Key Quality Standards for service appraisal

International Consortium on Quality in Substance Use Disorders Treatment

Insights from the Recipient of the first ICQ Quality Seal Award

PIQAT: Program for International Quality Assurance in Treatment

Synthetic cathinones in drug-related deaths – an alarming issue or triviality?

Trends in GHB use and harms in Australia

Emergence of semi-synthetic cannabinoids in Europe – a perspective from the European Union Early Warning System

A Collaborative Approach to New Drug Identification in an Emerging Drug Early Warning System

Achieving universal health coverage of opioid agonist treatment in Norway: a cost-utility analysis

Route-Dependent Subjective Effects of Medical Heroin in HAT: Implications for Treatment Trajectories

AN IMPLEMENTATION SCIENCE EVALUATION OF SCOTLAND’S FIRST HEROIN ASSISTED TREATMENT (HAT) FACILITY

Reduced health care utilization after entering opioid agonist treatment; change in mental and somatic health domains

Motivations for cocaine use: relation with drug use patterns, risks and how this informs prevention

Heavy drinking among ‘sober generation’ youth: a longitudinal study

Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study

‘Russian Roulette’: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction?

Self-therapeutic use of psilocybin, MDMA and ketamine among Dutch nightlife attendees.

Medical use of psychedelic substances: EUDA's monitoring of key developments

Oxycodone and Morphine use in hospitals and primary healthcare in Norway 2010-2021

Global utilization trends for weekly/monthly injectable buprenorphine (CAM2038) in the treatment of Opioid Use Disorder

Trends in the detection and co-detection of drugs in a population attending opioid agonist treatment: 2010 to 2020

Being Seen and Heard: Exploring the Relational Dimension of Heroin Assisted Treatment in Norway.

Death after residential treatment for opioid use disorder among people using fentanyl

The U.S. Psilocybin Landscape: Policy Evolution and Nationally Representative Insights

Mortality among long-term prescription opioid users

18:30

Why are we not doing better at reducing drug-related deaths?

18:30 to 19:30

Auditorium I

Thomas Clausen, Marie Jauffret-Roustide, Keith Humphreys, Paul Dietze, Katri Abel-Ollo

Thursday, 24 October

09:00

Keynote presentation

How will new strategies for addressing synthetic opioid and stimulant addiction impact the clinical and research agenda?

Will psychedelics play a more important role in the treatment of mental health problems in the future?

10:50

Overdoses in the drug consumption room in Oslo: route of administration matters!

Changes in the use of non-prescribed hydromorphone and unregulated opioids use in Vancouver, Canada, 2018-2022

Definition of public amenity in drug consumption room literature: A scoping review

Enhancing Harm Reduction: A Qualitative Evaluation of Athens' Drug Consumption Room

The Value of Peer Research: A Peer Perspective

Reasons for (non-)using a drug consumption room: the point of view of drug users.

Safe Inhalation Pipe Provision Study: Intervening to improve policy and practice for people who use crack in England.

A scoping review of mass media interventions intended to reduce stigma towards people who use drugs

Opioid disorder treatment outcomes — the OPTIMUS international consensus on evidence-based and patient-centred care

Cannabis policy and practice in Finland: from social media discussions to citizens initiatives

Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022

Perceptions of family physicians in Istanbul on e-cigarettes as smoking cessation aids

Key challenges for alcohol epidemiology and alcohol control policy evaluation

Health-related quality of life trajectories of patients in heroin-assisted treatment

Legally grey? Drug checking perspectives in the CEECA region

Public health for whom? Unpacking the assumptions and silences in Canada's public health approach to substance use.

The Costs and Harms of Substance Use in Canada: Key Trends from 2007 to 2022

A Holistic Multi-Disciplinary Healthcare Pathway for Older Men who use Anabolic Androgenic Steroids

A Global Perspective on Treatment Service Provision for Opioid Use Disorders

10:50 to 12:20

Auditorium III

Arash Khojasteh Zonoozi

Oral presentation

Drugs and climate change: knowledge gaps in monitoring environmental impacts of drugs

A wastewater-based approach to monitor shifting trends in illicit drugs consumption in Switzerland

What can Portugal do to prevent be caught off guard again in the drug domain?

European Hair Drug Analisys Network – A pioneer study to investigate the use of NPS and NSO

Synthesis of multisource data for the development of an advanced dashboard to monitor illicit drugs markets

Challenges, threats, and opportunities in addiction publishing today

10:50 to 12:20

Room 1.05

John Marsden, Matilda Hellman, Anees Bahji, Bryon Adinoff

13:20

Oral presentation

Acute nitazene-toxicity presentations to hospital emergency services, Dublin, Ireland, November 2023 outbreak

Acute drug toxicity outbreak with nitazenes involved in prison setting and the community, La Réunion, France, June-July 2023

Overview of the Cannabis Act and Cannabis Regulations

Post-mortem analytical findings and characteristics of the nitazene-related deaths cases, Finland, 2023

A Review of the Public Health and Safety Impacts of Cannabis of Legalization and Key Recommendations

Practical overview of management including naloxone dosing. Illustration with cases related to potent synthetic opioids, St Thomas’ hospital, 2023.

Looking Ahead: Future Priorities for Cannabis Research, Public Education, and Prevention

Cannabis use disorder and the brain: The role of cross-cultural differences in cannabis attitudes

Differential effects of left and right insula inhibition on craving and cognitive control in regular smokers

Vulnerabilities and agencies of women who use and sell drugs in Bordeaux and Montréal

Unveiling the Nexus of Addiction, Violence, and Risk: Generational Patterns in Female Populations

Female-specific trends and treatment needs for substance use disorder among homeless and at-risk females

Gender and drugs: Experiences of stigma/toxicophobia and narcofeminist narratives

13:20 to 14:50

Room 1.08

Marie Jauffret-Roustide

Oral presentation

Peripheral endocannabinoids and related lipids in individuals with chronic non-medical prescription opioid use

The genetic etiology of cannabis use: from twin models to genome-wide association studies and beyond

Pregnancy-related hospitalisation among women who inject drugs in Melbourne, Australia

A mixed methods systematic review of interventions for women in the perinatal period, who are dependent on drugs

The care pathways of women who use drugs in the perinatal period. Findings of a qualitative, longitudinal study

The perinatal period as a window of opportunity for change and recovery? A study of mothers and relatives' accounts

15:00

Background and establishment of the Addiction Clinical Care Suite (ACCS): a comprehensive, multi-disciplinary inpatient addiction service in London

The case of Kratom: from traditional medical to recreational use

15:00 to 16:30

Room 1.05

Vicknasingam Balasingam

Oral presentation

The Addiction Clinical Care Suite (ACCS): service outline and 2 year outcome data

Exploring Novel Psychoactive Substances Among Kazakhstan's Youth: A Focus on Emerging Trends and Risks

ACCS complexity of care provision

Emerging Drug trends in Japan: rethinking prevention strategies

Psychosocial Care

Experiences of building a Prompt Response Network for emerging drugs of concern in Australia

LECUCA: Analysis of Brazil's largest open drug scene using time-series cross-sectional survey data

Brorphine analogues as new psychoactive substances: in vitro and in vivo pharmacological characterization

25 years of monitoring the Dutch cannabis market using chemical analys: trends, developments and technical discussion

In vitro cannabinoid activity-based screening of seized plant materials: a future-proof harm reduction strategy?

Drug monitoring by samples seized at 2018, 2022 and 2023 BOOM festival editions

15:00 to 16:30

Room 1.08

Carla Filipa Ferreira

Oral presentation

Neurotoxicity of synthetic cathinones: Can metabolism play a role?

Trends in illicit and licit substance use across Spain – A comprehensive three-year wastewater-based epidemiology study.

Pharmacology of 30 semisynthetic cannabinoids – and why details matter when assessing the harm potential of seized drugs

Exploring the bioavailability and hepatotoxic effects of psychoactive chloro-cathinones.

Introducing the Theory of Preloading: A Cognitive-Behavioural Motivational Model

Synthetic cannabinoids ADB-FUBINACA and THJ-2201 dysregulate osteogenesis-related mechanisms in vitro

Epigenetic modulation of in vitro neurodifferentiation of NG108-15 cells by the synthetic cannabinoid THJ-2201

15:00 to 16:30

Room 1.06

Catarina Pereira-Teixeira

Short communication

Human-relevant concentrations of synthetic cannabinoid THJ-2201 alter mitochondrial dynamics during neurodifferentiation

Chronic alcohol exposure and thiamine transport in BBB in Alcohol Use Disorder

Unraveling the genetic architecture of smoking: pathways of genetic risk through addiction and socioeconomics

16:50

How can the voices of people with lived experience, clients and communities impacted by drug use better inform clinical practice, research and the policy agenda?

16:50 to 17:50

Auditorium I

Tony Duffin, Luís Mendão, Joanne Neale, Elizabeth (Elza) Berk, Judy Chang

Oral presentation

Data collection on acute drug toxicity using the Euro-DEN plus model in countries bordering the European Union

Inpatient admissions in people with opioid dependence: a portuguese population-based observational retrospective study

Acute drug-toxicity presentations involving polydrug use to Euro-DEN Plus sentinel hospitals in Europe from 2014 to 2022

Misuse of psychoactive medicines and its harmful consequences in Portugal

Socioeconomic risk factors for long-term prescription opioid use: A national registry-linkage study

Using intensive longitudinal data to investigate predictors of cannabis and opioid use among patients with chronic pain

Non-Fatal Overdose: A Decade-Long Analysis of Inner-City Hospitals and Nationwide Trends Across Ireland (2011-2021)

It is time to take nitrous oxide seriously

Nangs in Australia: Investigating nitrous oxide use among people who regularly use MDMA and/or other illicit stimulants

Population aging and apparent decline in initiation of injecting drug use in Australia

Cocaine use on the rise – are politicians and city level services prepared for the emerging trend of crack cocaine?

16:50 to 18:20

Auditorium III

Else Kristin Utne Berg

Oral presentation

Words vs. strands: Does the concordance of self-reported and hair-analyzed substance use of young adults change over time?

Understanding Drug Use in a Dutch Prison: A Call for Improved Research and Care and Lessons learned

New challenges for outpatient care: trends from twenty years of monitoring treatment demand in the city of Hamburg

ScaleUp: Options for scalable psychosocial and pharmacological treatment of stimulant use disorder

16:50 to 18:20

Room 1.08

Anja Busse, Didier Jutras-Aswad, Ivan Montoya, Nadine Ezard, Adam Bisaga

Oral presentation

Responding to the identification of nitazenes within the illicit diazepam market

17:50

EUDA presentation

17:50 to 18:20

Auditorium I

Alexis Goosdeel

Friday, 25 October

09:00

Keynote presentation

How well do our existing models of behavioural addictions fit with our understanding of substance use disorders?

Understanding the relationships between substance use disorders and other health outcomes, with a special focus on cancer

10:50

Revisiting Goldstein: A New Framework for Understanding Drug-Related Violence in a Globalised Era

Situation in Afghanistan: Opium cultivation and heroin production

An exploration of drug market, gun violence and sociodemographic patterns in Stockholm Sweden and the prediction of gun violence

Opium and heroin production in Southeast Asia

Homicides committed by criminal groups involved in Swedish drug distribution

Implications of heroin shortages in Europe: the emergence of synthetic opioids

The evolving situation with nitazenes in Ireland

Substance use patterns among young homicide offenders in Finland 2002-2022

What can we learn about poly-drug use among frequent cannabis users? results from the European Web Survey on Drugs

Drug use in French prisons. Results of the ESSPRI survey

Prison-based treatment needs for people with a history of substance use disorder: A nationwide cohort study

Substance use and psychological states in imprisoned population in Greece—Key findings from a recent nationwide survey

Online approach and characteristics of the hidden population with substance use disorder that doesn’t reach treatment

10:50 to 12:20

Room 5B

Ilias Paraskevopoulos

Oral presentation

Do Self-Report Drug Use Surveys Produce the Same Results in Print and Online Mode? Findings from a Dual Mode Survey.

An online survey of cannabis users and ex-users in Ireland

Psychedelic therapy in the treatment of addiction: the past, present and future

The old kid in the block: Unpacking signals of increased availability and use of ketamine

Current perspectives on the research and medical use of psychedelic drugs for alcohol addiction treatment

The Pharmacological Management of Ketamine Use Disorder: A Systematic Review

The ripple effect: International developments in the opioid market and their potential implications for European public health and security

13:20

Controlled cannabis supply chain experiment: state of affairs and lessons learned

Cannabis law reform in Switzerland: purpose, opportunities, and risks of local pilot projects

Issues of transport, driving safety & intoxication for opioid agonist treatment clients in New South Wales, Australia

Cannabis law reform in Luxembourg: first observations after its change among recreational cannabis users and non-users

Physical conditions and associated health service utilization among individuals with substance-related disorders

The effect of substance use disorders on vaccine uptake, acceptance, and adherence: a global systematic review

Cannabis law reform in Germany: a rocky road to a partial legalisation

Out of treatment drug and alcohol users in England: ‘Unmet Treatment Need’?

Drug an ALcohol Related Intoxication Among Young Adolecents in Palestine

New processes of normalisation? Understanding changes in young people's drug use in the UK.

Does Variation in Local Policy Mediate the Impact of Legal Cannabis Markets on Adolescent Cannabis Use?

13:20 to 14:50

Auditorium III

Rosalie Liccardo Pacula

Oral presentation

The (cost-)effectiveness of contingency management for cannabis use disorder in youth: A randomized controlled trial

15:00

WHO work to assessing needs and availability of training programmes for professionals in the substance misuse field

15:00 to 16:40

Auditorium I

Carina Ferreira-Borges

Keynote presentation

Understanding the potential future global impacts of the revolution in synthetic drug production and use

Amsterdam’s quest for sensible drug regulation

15:00 to 16:40

Auditorium I

Femke Halsema

Previous track View all tracks